Overview

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Status:
Unknown status

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to pegylated-interferon alpha and ribavirin.

Phase:

Phase 2

Details

Lead Sponsor:

Santaris Pharma A/S

Treatments:

Interferon-alpha
Interferons
Ribavirin